NTLA
Intellia Therapeutics, Inc
stockNASDAQ
intellia therapeutic's core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 11.42 | 2026-09-28 | +7.36% | -1.792 |
| 1M | 12.74 | 2026-09-04 | -3.77% | 1.752 |
| 3M | 17.84 | 2026-07-06 | -31.28% | 1.963 |
| 6M | 13.30 | 2026-04-06 | -7.82% | 2.156 |
| 1Y | 20.54 | 2025-10-06 | -40.31% | 2.243 |
| 2Y | 17.99 | 2024-10-04 | -31.85% | — |
| 5Y | 129.76 | 2021-10-05 | -90.55% | 1.944 |
Intellia Therapeutics, Inc (NASDAQ:NTLA) stock price today is $12.26, and today's volume is 4,503,688. NTLA is up 1.155% today. The 30 day average volume is 4.02M. NTLA market cap is $1.72B with 140.13M shares outstanding.